186Re-RNL (186Re-Rhenium Nano Liposome) is a non-specific locally irradiating drug (brachytherapy, delivered intra-tumorally) based on radiolabeled nanoliposomes for treatment of brain cancers.
This molecule entered a Phase I/II trial in 2015 (dose escalation study, tolerability and distribution in patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. This study is expected to be completed in 2025, but first data were published in 2021. Another Phase I study was initiated in 2021 (ReSPECT-LM study) in patients with Leptomeningeal Metastases.
Radiation Type: beta electrons (β–)